A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of cisplatin-induced toxicity in animal model?

Journal of Nephropathology

Volumn 1, Issue 3, 2012, Pages 190-193

  Nematbakhsh, Mehdi ^a,b   Ashrafi, Farzaneh ^a   Pezeshki, Zahra ^a   Fatahi, Zahra ^c   Kianpoor, Fariborz ^a   Sanei, Mohammad Hossein ^a   Talebi, Ardeshir ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Clinical Pathologist   (Iran)

Author keywords

Cisplatin; Hepatoxicity; Nephrotoxicity; Toxicity

Indexed keywords

EID: 84874747005     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/nephropathol.8122     Document Type: Article

References (21)

1. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, et al. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010;66(6):1087-93.
2. Bergs JW, Franken NA, Haveman J, Geijsen ED, Crezee J, van Bree C. Hyperthermia, cisplatin and radiation trimodality treatment: a promising cancer treatment? A review from preclinical studies to clinical application. Int J Hyperthermia. 2007;23(4):329-41.
3. Fujiyama J, Nakase Y, Osaki K, Sakakura C, Yamagishi H, Hagiwara A. Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J Control Release. 2003;89(3):397-408.
4. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293-308.
5. Saad AA, Youssef MI, El-Shennawy LK. Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract. Food Chem Toxicol. 2009;47(7):1499-506.
6. Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res. 2008;57(2):125-31.
7. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother. 1993;27(4):438-41.
8. Kohn S, Fradis M, Robinson E, Iancu TC. Hepatotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig. Ultrastruct Pathol. 2005;29(2):129-37.
9. Atessahin A, Sahna E, Turk G, Ceribasi AO, Yilmaz S, Yuce A, et al. Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats. J Pineal Res. 2006;41(1):21-7.
10. Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13(2):229-36.
11. Cherry SM, Hunt PA, Hassold TJ. Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation. Mutat Res. 2004;564(2):115-28.
12. Zhang X, Yamamoto N, Soramoto S, Takenaka I. Cisplatin- induced germ cell apoptosis in mouse testes. Arch Androl. 2001;46(1):43-9.
13. Huddart RA, Titley J, Robertson D, Williams GT, Horwich A, Cooper CS. Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. Eur J Cancer. 1995;31A(5):739-46.
14. Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril. 1997;68(1):1-5.
15. Sawhney P, Giammona CJ, Meistrich ML, Richburg JH. Cisplatin-induced long-term failure of spermatogenesis in adult C57/Bl/6J mice. J Androl. 2005;26(1):136-45.
16. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol. 2008;28(3):337-44.
17. Custodio JB, Cardoso CM, Santos MS, Almeida LM, Vicente JA, Fernandes MA. Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology. 2009;259(1-2):18-24.
18. Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, et al. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25(3):410-7.
19. Liu XH, Li J, Li QX, Ai YX, Zhang L. Protective effects of ligustrazine on cisplatin-induced oxidative stress, apoptosis and nephrotoxicity in rats. Environ Toxicol Pharmacol. 2008;26(1):49-55.
20. Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol. 2008;61(1):145-55.
21. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81(7):495-504.